比伐卢定与肝素：这场较量远未结束？：疗效、安全性和成本仍是治疗ST段抬高型心肌梗死的战场。
Bivalirudin Versus Heparin: A Fight Far From Finished?: Efficacy, Safety, and Cost Remain Battlegrounds for the Treatment Of ST-Segment Elevation Myocardial Infarction.
作者信息
Alexander Walter
出版信息
P T. 2015 Mar;40(3):209-17.
Abstract
A strident debate has been surging in the interventional cardiology community over the triumvirate of efficacy, safety, and cost of bivalirudin compared with heparin for anticoagulation of patients with ST-segment elevation myocardial infarction.
摘要
在介入心脏病学界，一场激烈的辩论正在激烈进行，内容是关于比伐卢定与肝素相比，用于ST段抬高型心肌梗死患者抗凝时在疗效、安全性和成本这三方面的情况。
相似文献
1
2
Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
Circ Cardiovasc Interv. 2012 Oct;5(5):705-12. doi: 10.1161/CIRCINTERVENTIONS.112.972869. Epub 2012 Oct 9.
3
Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin Versus Heparin: A Report From the National Cardiovascular Data Registry.
JACC Cardiovasc Interv. 2017 Jun 12;10(11):1102-1111. doi: 10.1016/j.jcin.2017.03.021. Epub 2017 May 17.
4
Efficacy and safety of prehospital administration of unfractionated heparin, enoxaparin or bivalirudin in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Insights from the ORBI registry.
Arch Cardiovasc Dis. 2016 Dec;109(12):696-707. doi: 10.1016/j.acvd.2015.10.007. Epub 2016 Nov 3.
5
Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.
N Engl J Med. 2011 Nov 24;365(21):1980-9. doi: 10.1056/NEJMoa1109596. Epub 2011 Nov 13.
6
Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
Am J Cardiol. 2014 Jul 15;114(2):250-9. doi: 10.1016/j.amjcard.2014.04.033. Epub 2014 May 2.
7
Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry.
Circ Cardiovasc Interv. 2014 Jun;7(3):365-73. doi: 10.1161/CIRCINTERVENTIONS.113.001126. Epub 2014 Apr 15.
8
Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction-a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial).
Am Heart J. 2016 May;175:36-46. doi: 10.1016/j.ahj.2016.02.007. Epub 2016 Feb 20.
9
Bivalirudin in ST-segment-elevation myocardial infarction: for better or worse?
Expert Rev Cardiovasc Ther. 2015;13(8):893-5. doi: 10.1586/14779072.2015.1064311. Epub 2015 Jul 2.
10
Heparin Versus Bivalirudin Monotherapy in the Setting of Primary Percutaneous Coronary Intervention for Patients With ST-Segment Elevation Myocardial Infarction.
Ann Pharmacother. 2016 Feb;50(2):141-51. doi: 10.1177/1060028015618206. Epub 2015 Dec 17.
引用本文的文献
1
Differential Use of Glycoprotein IIb/IIIa Inhibitors with Bivalirudin in Patients with STEMI Undergoing PCI: A Systematic Review and Meta-Analysis.
Am J Cardiovasc Drugs. 2024 May;24(3):385-398. doi: 10.1007/s40256-024-00636-6. Epub 2024 Apr 29.
2
New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?
Molecules. 2016 Feb 27;21(3):284. doi: 10.3390/molecules21030284.
本文引用的文献
1
Choice of optimal anticoagulant to support primary PCI: out with the new, in with the old.
J Am Coll Cardiol. 2015 Jan 6;65(1):39-42. doi: 10.1016/j.jacc.2014.11.002.
2
Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.
J Am Coll Cardiol. 2015 Jan 6;65(1):27-38. doi: 10.1016/j.jacc.2014.10.029.
3
Real-time decision support to guide percutaneous coronary intervention bleeding avoidance strategies effectively changes practice patterns.
Circ Cardiovasc Qual Outcomes. 2014 Nov;7(6):960-7. doi: 10.1161/CIRCOUTCOMES.114.001275. Epub 2014 Nov 4.
4
Bivalirudin started during emergency transport for primary PCI.
N Engl J Med. 2013 Dec 5;369(23):2207-17. doi: 10.1056/NEJMoa1311096. Epub 2013 Oct 30.
5
Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction).
J Am Coll Cardiol. 2014;63(1):15-20. doi: 10.1016/j.jacc.2013.09.027. Epub 2013 Oct 16.
6
Bivalirudin therapy is associated with improved clinical and economic outcomes in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention: results from an observational database.
Circ Cardiovasc Qual Outcomes. 2012 Jan;5(1):52-61. doi: 10.1161/CIRCOUTCOMES.111.961938. Epub 2012 Jan 10.
7
The effect of bivalirudin on costs and outcomes of treatment of ST-segment elevation myocardial infarction.
Am Heart J. 2011 Sep;162(3):494-500.e2. doi: 10.1016/j.ahj.2011.05.019. Epub 2011 Jul 26.
8
Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial.
Lancet. 2011 Jun 25;377(9784):2193-204. doi: 10.1016/S0140-6736(11)60764-2. Epub 2011 Jun 12.
9
Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.
Hosp Pract (1995). 2010 Nov;38(4):138-46. doi: 10.3810/hp.2010.11.351.
10
Bivalirudin during primary PCI in acute myocardial infarction.
N Engl J Med. 2008 May 22;358(21):2218-30. doi: 10.1056/NEJMoa0708191.
Zotero 插件